ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.44
0.90%
US Tech 100
20,817.20
1.22%
S&P 500
5,944.87
1.33%
US Dollar vs CAD
1.43729
-0.21%
Bitcoin
97,313.21
-0.15%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Xilio Therapeutics Inc (XLO)

  7. Xilio Therapeutics Inc (XLO) News

Xilio Therapeutics Inc

Xilio Therapeutics Inc (XLO)

NASDAQ
1.0618
0.1238
( 13.20% )
Updated: 10:13:32
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

XLO News

Official News Only

Form 8-K - Current report
Edgar (US Regulatory)
December 19 2024
XLO (13.20%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
November 07 2024
XLO (13.20%)

Form 8-K - Current report
Edgar (US Regulatory)
November 07 2024
XLO (13.20%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
October 02 2024
XLO (13.20%)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Edgar (US Regulatory)
September 27 2024
XLO (13.20%)

XLO Discussion

View Posts
tbonaces80 tbonaces80 7 hours ago
Strike is easily $1.97. News or approval and we go hard
👍️0
tbonaces80 tbonaces80 16 hours ago
Loaded a nice position here
👍️0
Preciouslife1 Preciouslife1 19 hours ago
https://ir.xiliotx.com/news-releases/news-release-details/xilio-therapeutics-present-initial-phase-2-data-vilastobart
👍 1
PonkenPlonken PonkenPlonken 3 weeks ago
trades below cash value
Makes no f in sense!
stick it out......
👍️ 1
Preciouslife1 Preciouslife1 1 month ago
https://ir.xiliotx.com/news-releases/news-release-details/xilio-therapeutics-announces-initial-clinical-trial-data-phase
👍️0
TrendTrade2016 TrendTrade2016 2 months ago
XLO HERE WE GO
👍️0
TrendTrade2016 TrendTrade2016 2 months ago
BIO BEAST
👍️0
TrendTrade2016 TrendTrade2016 2 months ago
XLO MONSTER BREAK
👍 1
TrendTrade2016 TrendTrade2016 2 months ago
XLO BUILDING STEAM
👍 1
PonkenPlonken PonkenPlonken 2 months ago
running towards two readouts with Gilead sitting at 17% ownership at 1.97$ strike. I have the hubris to say this WILL GO GO
👍️0
TrendTrade2016 TrendTrade2016 2 months ago
XLO HERE WE GO
👍️0
PonkenPlonken PonkenPlonken 2 months ago
COMING TO LIFE
masked antibodies
👍 1
TrendTrade2016 TrendTrade2016 2 months ago
XLO...MINI BIO BEAST
👍 1
Laster Laster 2 months ago
Got some at $1.00 several days ago.
I like the share structure. It might run for a few days.
Looking for $1.40 if I am lucky.
👍️ 1
Preciouslife1 Preciouslife1 2 months ago
https://ir.xiliotx.com/news-and-events/news-releases
👍️ 1
Preciouslife1 Preciouslife1 3 months ago
https://www.linkedin.com/posts/hashem-al-ghaili-1b30679b_drug-resistant-bacteria-are-projected-to-activity-7246464071565201410-sAL9?utm_source=share&utm_medium=member_ios
👍️0
Preciouslife1 Preciouslife1 4 months ago
This information makes one wonder IF BRILICIDIN IS BEING SUPPRESSED TOO: https://www.facebook.com/share/r/MTAzjcdR5iGnab4t/?mibextid=6GsUZ4
👍️ 1
Preciouslife1 Preciouslife1 4 months ago
https://www.gilead.com/news-and-press/press-room/press-releases/2024/3/gilead-and-xilio-announce-exclusive-license-agreement-for-tumor-activated-il-12-program
👍️0
PonkenPlonken PonkenPlonken 4 months ago
Gilead paid 13.5mn$ @ 1.97
The results of their partnered program and another one will be reported in Q4 24
masked antibodies... very little toxicity.
I have a small position... Think big rally coming into 2025- atleast to the 1.97 strike.


"Under the License Agreement, the Company will receive approximately $43.5 million in upfront payments, including a cash payment of $30.0 million and an initial equity investment by Gilead of approximately $13.5 million in the Company’s common stock, $0.0001 par value per share (the “Common Stock”), at a purchase price of $1.97 per share. The Company will be eligible to receive up to $604.0 million in additional contingent payments, which include (i) the proceeds from up to three additional private placements of Common Stock, (ii) the $75.0 million transition fee and (iii) specified development, regulatory and sales-based milestones. Prior to the potential transition fee, up to $29.0 million of the total contingent payments are related to the potential additional private placements of Common Stock and a near-term development milestone. In addition, the Company is eligible to receive tiered royalties ranging from high single digits to mid-teens on annual global net product sales."

"In addition, through March 27, 2025, the Company may, at its election and subject to the terms and conditions of the Stock Purchase Agreement, cause Gilead to purchase up to approximately $11.5 million of additional shares of Common Stock (including, at Gilead’s sole election, prefunded warrants in lieu of shares of Common Stock) in up to three additional private placements (each, an “Additional Gilead Private Placement”) at a predetermined price per share..."
👍️ 1
PonkenPlonken PonkenPlonken 7 months ago
XLO -- unique masking approach and great results. Hot field $JANX. Gilead certainly thinks so - buys real equity. Company trades below the upfront payment...

https://schrts.co/tdtYZDEX
👍️0
Preciouslife1 Preciouslife1 7 months ago
Hi I tried to buy a bunch of shares this morning once at .885 then at .90; never filled though over the ASK PRICE then it took off upwards! MM MANIPULATION MUCH!?!?
👍️0
Laster Laster 8 months ago
Stock closed the gap. They are in the right biotech area similar to CLRB and CTMX and SNSE.
Only a matter of time before this explodes to $2 or higher.
JMO.
👍️0
Monksdream Monksdream 8 months ago
XLO under $2
👍️0
Laster Laster 8 months ago
The chart shows a very nice looking pennant pattern.
Biotechs are not trading well recently.
Any recovery in biotechs then this could get interesting.
Needs to move past $1.50 to confirm breakout.
Enjoy the day.
👍️0
Laster Laster 8 months ago
I remember when OCEA had similar pennant pattern before it broke out to $7.50.
Crazy times sometimes causes crazy moves.
I like the story here. Seems like a nice biotech to invest into.
JMO.
Enjoy.
👍️0
Laster Laster 8 months ago
Oops. I blinked. Missed it.
Maybe I will be quicker when it moves back to $1.20.
Unless it pops to $1.50 on no news.
Chart looks interesting. Nice pennant pattern.
Enjoy.
👍️0
Awl416 Awl416 8 months ago
Don’t blink
👍️0
Invest-in-America Invest-in-America 9 months ago
XLO: Best of luck on this one, Capt. TIm!! (I DID get both of your Post-M iHub 'emails', so I am answering both of them vis-a-vis this single one.) I am still in SHOCK that XLO did NOT soar at least 400% today.

WILD, UNPREDICTABLE, DAY TODAY!!! (And I missed all the glory behind @AVTX, to boot!! BUMMER!!!)
👍️0
TIMGZ TIMGZ 9 months ago
XLO IS MOVING , HOPEFULLY THE TORTOISE-LIKE CONTINUES*****
IN THE NEXT 3 HOURS AND PR MONDAY SHOULD BE MORE GLORIOUS****WE SHALL SEE***


THAT WAS AN EXCELLENT PR BUT THE PLAN ALL ALONG WAS SNAKE-OIL-LIKE
👍️0
Invest-in-America Invest-in-America 9 months ago
XLO: Worthless piece of SHIT!!!
👍️0
Invest-in-America Invest-in-America 9 months ago
XLO: Oooooooo, Boy!!! (Latest 'Chart', below, looks pretty good!!!)




"I gots my entire weekly ALLOWANCE in this, sucka!!! So you BETTER gets to Planet Jupiter pretty damn QUICK!!!"
👍️0
Invest-in-America Invest-in-America 9 months ago
XLO: Halted.
👍️0
JPetroInc JPetroInc 9 months ago
nice news on XLO

looks a lot like iBio news

good fortunes to all XLO shareholders …

EOM
👍️0
Awl416 Awl416 9 months ago
Watch out for these dirty algo’s
👍️0
Awl416 Awl416 9 months ago
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
👍️0
Awl416 Awl416 9 months ago
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
👍️0
crudeoil24 crudeoil24 3 years ago
Price target > 36.00 > HC Wainwright & Co. analyst Michael King initiates coverage on Xilio Therapeutics (NASDAQ:XLO) with a Buy rating and announces Price Target of $36.

Latest Ratings for XLO DateFirmActionFromTo

Jan 2022HC Wainwright & Co.Initiates Coverage OnBuy Nov 2021Raymond JamesInitiates Coverage OnOutperform Nov 2021Cowen & Co.Initiates Coverage OnOutperform

👍️0
crudeoil24 crudeoil24 3 years ago
TODAY > Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that Rene Russo, Pharm. D., president and chief executive officer, and Marty Huber, M.D., president of research and development and chief medical officer of Xilio Therapeutics, will participate in a virtual fireside chat during the Guggenheim 4 Annual Oncology Day on Thursday, February 10, 2022, at 8:30 a.m. ET.

A live webcast will be available in the Investors and Media section of the Xilio Therapeutics' website at https://ir.xiliotx.com. A replay of the webcast will be archived on Xilio Therapeutics' website for 30 days following the presentation.
👍️0
crudeoil24 crudeoil24 3 years ago
Xilio Therapeutics, Inc. is a biotechnology company. The Company is focused on harnessing the immune system to achieve clinical responses for cancer patients. It offers a geographically precise solutions (GPS) platform to engineer molecules, including cytokines and other biologics, that are designed to enhance therapeutic index. Using its GPS platform, the Company is engaged in developing a pipeline of tumor-selective cytokine and checkpoint inhibitor immunotherapies to treat cancer. Its product candidates include XTX101, XTX202, XTX301, and XTX401. XTX101 is a clinical-stage, tumor-selective anti-cytotoxic T-lymphocyte-associated protein (CTLA-4), monoclonal antibody (mAb), which is designed to improve upon the therapeutic index of existing anti-CTLA-4 therapies. XTX202 and XTX301 are an engineered form of interleukin 2 (IL-2) that is masked with a protein domain to prevent binding activity
👍️0

Your Recent History

NASDAQ
XLO
Xilio Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads